A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 74, Issue 9, 2003, Pages 1225-1230

  Craig, J ^a   Young, C A ^a   Ennis, M ^a   Baker, G ^b   Boggild, M ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MALE; MEDICAL ASSESSMENT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERPROFESSIONAL RELATIONS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT CARE TEAM; PHYSICAL THERAPY MODALITIES; RECURRENCE; TREATMENT OUTCOME;

EID: 0141740713     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.9.1225     Document Type: Article

References (31)

1. Compston A. Genetic susceptibility to multiple sclerosis. In: Compston A, Ebers G, Lassmann H, et al, eds. McAlpine's multiple sclerosis, 3rd edn. London: Churchill Livingstone, 1998:104-44.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
3. Young CA. Improving the care of patients with progressive multiple sclerosis: an evidence-based approach. J R Coll Physicians 2002;32:79-23.
4. Goodkin DE. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. West J Med 1994; 161:292-8.
5. Taggart HM. Multiple sclerosis update. Orthop Nuts 1998:23-9.
6. Barnes D, Hughes RAC, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of MS. Lancet 1997;349:902-6.
7. Fillipini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis (Cochrane review). The Cochrane Library, Issue 4, Oxford, 2000.
8. Tremelett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the UK. J Neurol Neurosurg Psychiatry 1998;65:362-5.
9. Stevenson VL, Thompson AJ. The management of MS: current and future therapies. Drugs of Today 1998;34:267-82.
10. Mertin J. Rehabilitation in MS. Ann Neurol 1994;36(suppl):S130-3.
11. De Souza LH, Worthington JA. The effect of long-term physiotherapy on disability in multiple sclerosis patients. In: Rose FC, Jones R, eds. MS: immunological, diagnostic and therapeutic aspects. Current problems in neurology, No 3. London and Paris: John Libbey Eurotext, 1987:155-67.
12. Fuller KJ, Dawson K, Wiles CM. Physiotherapy in chronic MS: a controlled trial. Clin Rehabil 1996;10:195-204.
13. Lord SE, Wade DT, Halligan PW. A comparison of two physiotherapy treatment approaches to improve walking in MS: a pilot randomised control study. Clin Rehabil 1998;12:477-86.
14. Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic MS. J Neurol Neurosurg Psychiatry 2001;70:174-9.
15. Jones L, Lewis Y, Harrison J, et al. The effectiveness of OT and PT in MS patients with ataxia of the upper limb and trunk. Clin Rehabil 1996;10:277-82.
16. Freeman JA, Langdon DW, Hobart JC, et al. The impact of in-patient rehabilitation on progressive MS. Ann Neurol 1997;42:236-44.
17. Freeman JA, Langdon DW, Hobart JC, et al. Inpatient rehabilitation in multiple sclerosis - do the benefits carry over into the community? Neurology 1999;52:50-6.
18. Kidd D, Howard RS, Losseff NA, et al. The benefit of in-patient neurorehabilitation in MS. Clin Rehabil 1995;9:198-203.
19. Kidd D, Thompson AJ. Prospective study of neurorehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;62:423-4.
20. Bethoux F, Miller DM, Kinkel RP. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life. Mult Scler 2001;7:137-42.
21. Sharrack B, Hughes RAC. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999;5:223-33.
22. De Souza LH, Ashburn A. Assessment of motor function in people with MS. Physiother Res Int 1996;1:98-111.
23. Collin C, Wade DT, Davies S, et al. The Barthel ADL Index: a reliability study. Int Disabil Stud 1988;10:61-3.
24. Daughton D, Fix AJ, Kass I, et al. Maximum oxygen consumption and the ADAPT quality of life scale. Arch Phys Med Rehabil 1982;63:620-2.
25. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. conceptual framework. Med Care 1992;30:473-83.
26. Craig J, Young CA, Boggild M, et al. A study comparing multidisciplinary rehabilitation against standard therapy in multiple sclerosis patients receiving steroid treatment after relapse. Mult Scler 1999;5:S129.
27. Hoogervorst EJL, Kalkers NF, Van Winsen LML, et al. Differential treatment effect on measures of neurologic exam, functional impairment and patient self report in multiple sclerosis. Mult Scler 2001;7:335-9.
28. Miller CM, Hens M. MS: a literature review. J Neurosci Nurs 1993;25:174-9.
29. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27(suppl):178-89.
30. Freeman JA, Langdon DW, Hobart JC, et al. Health related quality of life in people with MS undergoing inpatient rehabilitation. J Neurol Rehabil 1996;10:185-94.
31. Freeman JA, Hobart JC, Langdon DW, et al. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:150-6.